Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Petros Grivas, MD, PhD, of University of Washington School of Medicine, about the impact of avelumab (Bavencio) on patients with advanced urothelial carcinoma in the first-line maintenance setting.
Data from the phase 2 JAVELIN Bladder 100 trial (NCT02603432), which examined the agent in patients with unresectable locally advanced or metastatic disease, reinforced that if patients were are treated with avelumab in the first-line maintenance setting, the time spent on the first- and second-line therapy was prolonged vs best supportive care.
The data from this particular abstract reinforced that if [patients] get avelumab as a maintenance therapy, the time that [they] spent in the first- and second-line therapy is prolonged compared [with] patients who [received] best supportive care. It was very difficult for us to granularly evaluate the progression-free survival in the subsequent line of therapy [following] progression in the maintenance trial. [However], with this abstract, we tried to estimate the overall time that [patients] spent in the first 2 lines of therapy after randomization. The data, if anything, substantiate or reinforce the benefit that avelumab has as a switch maintenance therapy in this population.
Grivas P, Park SH, Voog E, et al. Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line therapy in JAVELIN Bladder 100. J Clin Oncol. 2021;39(suppl 15):4525. doi:10.1200/JCO.2021.39.15_suppl.4525